Method for the treament of multiple myeloma or non-hodgkins lymphoma with anti-CD38 antibody in combination with thalidomine, lenalidomids, or pomalidomide
AssigneeMorphosys AG
InventorsLisa Rojkjaer, Rainer Boxhammer, Jan Endell, Mark Winderlich, Christofer Samuelsson
Life of this patent
Estimating the term…
Abstract
The present disclosure is directed to a method of treating multiple myeloma or non-hodgkins lymphoma with a pharmaceutical composition comprising an anti-CD38 antibody in combination with thalidomide, lenalidomide, or pomalidomide.
Claims20
A method for treating multiple myeloma or non-hodgkins lymphoma in a subject in need thereof, wherein said method comprises administering to the subject a therapeutically effective amount of a combination of:
- (i) thalidomide, lenalidomide or pomalidomide, (ii) an antibody specific for CD38, comprising an HCDR1 region of sequence SYYMN (SEQ ID NO:
- 14) or GFTFSSYYMN (SEQ ID NO:
- 1), an HCDR2 region of sequence GISGDPSNTYYADSVKG (SEQ ID NO:
- 2), an HCDR3 region of sequence DLPLVYTGFAY (SEQ ID NO:
- 3), an LCDR1 region of sequence SGDNLRHYYVY (SEQ ID NO:
- 4), an LCDR2 region of sequence GDSKRPS (SEQ ID NO:
- 5), and an LCDR3 region of sequence QTYTGGASL (SEQ ID NO:
- 6).
A method for treating multiple myeloma or non-hodgkins lymphoma in a subject in need thereof, wherein said method comprises administering to the subject a therapeutically effective amount of a combination of:
- thalidomide and an antibody specific for CD38, comprising an HCDR1 region of sequence SYYMN (SEQ ID NO:
- 14) or GFTFSSYYMN (SEQ ID NO:
- 1), an HCDR2 region of sequence GISGDPSNTYYADSVKG (SEQ ID NO:
- 2), an HCDR3 region of sequence DLPLVYTGFAY (SEQ ID NO:
- 3), an LCDR1 region of sequence SGDNLRHYYVY (SEQ ID NO:
- 4), an LCDR2 region of sequence GDSKRPS (SEQ ID NO:
- 5), and an LCDR3 region of sequence QTYTGGASL (SEQ ID NO:
- 6).
A method for treating multiple myeloma or non-hodgkins lymphoma in a subject in need thereof, wherein said method comprises administering to the subject a therapeutically effective amount of a combination of:
- lenalidomide and an antibody specific for CD38, comprising an HCDR1 region of sequence SYYMN (SEQ ID NO:
- 14) or GFTFSSYYMN (SEQ ID NO:
- 1), an HCDR2 region of sequence GISGDPSNTYYADSVKG (SEQ ID NO:
- 2), an HCDR3 region of sequence DLPLVYTGFAY (SEQ ID NO:
- 3), an LCDR1 region of sequence SGDNLRHYYVY (SEQ ID NO:
- 4), an LCDR2 region of sequence GDSKRPS (SEQ ID NO:
- 5), and an LCDR3 region of sequence QTYTGGASL (SEQ ID NO:
- 6).
A method for treating multiple myeloma or non-hodgkins lymphoma in a subject in need thereof, wherein said method comprises administering to the subject a therapeutically effective amount of a combination of:
- pomalidomide and an antibody specific for CD38, comprising an HCDR1 region of sequence SYYMN (SEQ ID NO:
- 14) or GFTFSSYYMN (SEQ ID NO:
- 1), an HCDR2 region of sequence GISGDPSNTYYADSVKG (SEQ ID NO:
- 2), an HCDR3 region of sequence DLPLVYTGFAY (SEQ ID NO:
- 3), an LCDR1 region of sequence SGDNLRHYYVY (SEQ ID NO:
- 4), an LCDR2 region of sequence GDSKRPS (SEQ ID NO:
- 5), and an LCDR3 region of sequence QTYTGGASL (SEQ ID NO:
- 6).
Dependencies are inferred from the claim text.